Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted drug hunts down cancer cells in advanced bladder cancer trial

NCT ID NCT02091999

Completed Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other solid tumors that express Nectin-4. The goal is to evaluate the drug's safety, how the body processes it, and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4 on cancer cells and delivers a chemotherapy agent directly to them
What this could lead to
If successful, this could provide a new treatment option for people with advanced bladder cancer and other cancers that express Nectin-4.
What could go wrong
This is an early phase 1 trial, so the drug may not prove effective or could cause significant side effects. The results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer non-small cell lung carcinoma ovarian carcinoma primary peritoneal carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS

Contacts and locations

Locations

  • Site CA00001

    Edmonton, Alberta, T6G 1Z2, Canada

  • Site CA00010

    Toronto, Ontario, M5G 2M9, Canada

  • Site CA00011

    Calgary, Alberta, T2N 4N2, Canada

  • Site US00002

    New York, New York, 10065, United States

  • Site US00003

    Detroit, Michigan, 48201, United States

  • Site US00004

    Fairway, Kansas, 66205, United States

  • Site US00005

    Ann Arbor, Michigan, 48109, United States

  • Site US00006

    New Haven, Connecticut, 06520, United States

  • Site US00007

    Miami, Florida, 33136, United States

  • Site US00008

    Tampa, Florida, 33612, United States

  • Site US00009

    Madison, Wisconsin, 53792, United States

  • Site US00012

    Los Angeles, California, 90033, United States

  • Site US00013

    Philadelphia, Pennsylvania, 19111, United States

  • Site US00015

    Milwaukee, Wisconsin, 53226, United States

  • Site US00017

    Aurora, Colorado, 80045, United States

  • Site US00018

    New York, New York, 10029, United States

  • Site US00019

    Stanford, California, 94305, United States

  • Site US00020

    Pittsburgh, Pennsylvania, 15232, United States

  • Site US00021

    Las Vegas, Nevada, 89119, United States

  • Site US00023

    Chapel Hill, North Carolina, 27599, United States

  • Site US00024

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.